Published in J Med Chem on August 28, 2003
Mast cell peptidases: chameleons of innate immunity and host defense. Am J Respir Cell Mol Biol (2009) 1.58
Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1. J Immunol (2008) 1.34
Synthesis of high enantiopurity N-protected alpha-amino ketones by thiol ester-organostannane cross-coupling using pH-neutral conditions. Org Lett (2008) 0.96
A copper-catalyzed, pH-neutral construction of high-enantiopurity peptidyl ketones from peptidic s-acylthiosalicylamides in air at room temperature. Angew Chem Int Ed Engl (2009) 0.96
Human subjects are protected from mast cell tryptase deficiency despite frequent inheritance of loss-of-function mutations. J Allergy Clin Immunol (2009) 0.87
Design and evaluation of Trypanosoma brucei metacaspase inhibitors. Bioorg Med Chem Lett (2010) 0.84
Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors. J Med Chem (2014) 0.77
Comprehensive Analysis of Structure-Activity Relationships of α-Ketoheterocycles as sn-1-Diacylglycerol Lipase α Inhibitors. J Med Chem (2015) 0.76
Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. ACS Med Chem Lett (2016) 0.75
Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature (2008) 3.14
Aerosolized red-tide toxins (brevetoxins) and asthma. Chest (2007) 2.70
The porcine lung as a potential model for cystic fibrosis. Am J Physiol Lung Cell Mol Physiol (2008) 2.53
Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood (2003) 2.20
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest (2007) 2.09
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Gaussian docking functions. Biopolymers (2003) 1.82
Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb Vasc Biol (2004) 1.67
Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem (2006) 1.63
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation (2006) 1.60
Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res (2008) 1.50
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Low-volume resuscitation from traumatic hemorrhagic shock with Na+/H+ exchanger inhibitor. Crit Care Med (2009) 1.41
Resuscitation with Na+/H+ exchanger inhibitor in traumatic haemorrhagic shock: cardiopulmonary performance, oxygen transport and tissue inflammation. Clin Exp Pharmacol Physiol (2009) 1.39
Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol (2007) 1.33
Protection against acute pancreatitis by activation of protease-activated receptor-2. Am J Physiol Gastrointest Liver Physiol (2004) 1.29
Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med (2006) 1.25
Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo. FASEB J (2003) 1.22
Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther (2003) 1.20
Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol (2009) 1.19
Thrombogenic collagen-mimetic peptides: Self-assembly of triple helix-based fibrils driven by hydrophobic interactions. Proc Natl Acad Sci U S A (2008) 1.18
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Participation of protease-activated receptor-1 in thrombin-induced microglial activation. J Neurochem (2002) 1.12
Review of Florida Red Tide and Human Health Effects. Harmful Algae (2011) 1.12
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. J Med Chem (2005) 1.12
Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther (2008) 1.11
Plasmin induces Cyr61 gene expression in fibroblasts via protease-activated receptor-1 and p44/42 mitogen-activated protein kinase-dependent signaling pathway. Arterioscler Thromb Vasc Biol (2002) 1.10
Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol (2002) 1.10
Neutrophil cathepsin G promotes detachment-induced cardiomyocyte apoptosis via a protease-activated receptor-independent mechanism. J Biol Chem (2003) 1.10
Collagen-related peptides: self-assembly of short, single strands into a functional biomaterial of micrometer scale. J Am Chem Soc (2007) 1.09
Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol (2006) 1.07
Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther (2008) 1.06
Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther (2004) 1.05
Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol (2003) 1.05
Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol (2005) 1.04
Expression of protease-activated receptor-1, -2, -3, and -4 in control and experimentally inflamed mouse bladder. Am J Pathol (2003) 1.04
Multiple mechanisms of vascular smooth muscle relaxation by the activation of proteinase-activated receptor 2 in mouse mesenteric arterioles. Br J Pharmacol (2002) 1.03
Synthesis of macrocycles via cobalt-mediated [2 + 2 + 2] cycloadditions. J Am Chem Soc (2005) 1.02
Exposure and effect assessment of aerosolized red tide toxins (brevetoxins) and asthma. Environ Health Perspect (2009) 1.00
Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol (2003) 1.00
Mechanisms of protease-activated receptor-4 actions in cardiomyocytes. Role of Src tyrosine kinase. J Biol Chem (2003) 0.99
Molecules that mimic apolipoprotein A-I: potential agents for treating atherosclerosis. J Med Chem (2013) 0.98
A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem (2005) 0.96
Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem (2004) 0.95
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem (2007) 0.95
Receptor-mediated enhancement of beta adrenergic drug activity by ascorbate in vitro and in vivo. PLoS One (2010) 0.95
Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J Am Chem Soc (2013) 0.94
An Epidemiologic Approach to the Study of Aerosolized Florida Red Tides. Harmful Algae 2002 (2002) (1) 0.94
Tryptase: potential role in airway inflammation and remodeling. Am J Physiol Lung Cell Mol Physiol (2002) 0.94
Synthesis, modeling, and biological evaluation of analogues of the semisynthetic brevetoxin antagonist beta-naphthoyl-brevetoxin. Chembiochem (2007) 0.93
Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am J Respir Cell Mol Biol (2006) 0.93
Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J Immunol (2007) 0.93
Regulatory network of inflammation downstream of proteinase-activated receptors. BMC Physiol (2007) 0.93
Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am J Respir Crit Care Med (2009) 0.92
Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J Pharmacol Exp Ther (2002) 0.92
Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem (2007) 0.92
Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation. BMC Physiol (2007) 0.91
Hyaluronan blocks human neutrophil elastase (HNE)-induced airway responses in sheep. Pulm Pharmacol Ther (2003) 0.91
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther (2007) 0.91
Characterization of tamulamides A and B, polyethers isolated from the marine dinoflagellate Karenia brevis. J Nat Prod (2010) 0.91
Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem (2009) 0.90
Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem (2006) 0.89
Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett (2007) 0.89
Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis (2005) 0.89
Therapeutic potential of protease-activated receptor-1 antagonists. Expert Opin Investig Drugs (2003) 0.89
Therapeutic targeting of endothelial ligands for L-selectin (PNAd) in a sheep model of asthma. Am J Pathol (2005) 0.88
Structural aspects of Rab6-effector complexes. Biochem Soc Trans (2009) 0.87
RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev (2003) 0.87
Na+/H+ exchange inhibition delays the onset of hypovolemic circulatory shock in pigs. Shock (2008) 0.87
The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett (2003) 0.86
Inhibition of spleen tyrosine kinase attenuates allergen-mediated airway constriction. Am J Respir Cell Mol Biol (2013) 0.86
Intrathecal administration of proteinase-activated receptor-2 agonists produces hyperalgesia by exciting the cell bodies of primary sensory neurons. J Pharmacol Exp Ther (2007) 0.86
Lipofuscin and Abeta42 exhibit distinct distribution patterns in normal and Alzheimer's disease brains. Neurosci Lett (2002) 0.86
Mechanisms underlying the nociceptive and inflammatory responses induced by trypsin in the mouse paw. Eur J Pharmacol (2007) 0.86
Nonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion. Am J Physiol Lung Cell Mol Physiol (2013) 0.85
Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl (2002) 0.85
7-fluoroindazoles as potent and selective inhibitors of factor Xa. J Med Chem (2007) 0.85
Cobalt-mediated cyclotrimerisation of bis-alkynes and cyanamides. Chem Commun (Camb) (2004) 0.85
Comparative effects of salmeterol, albuterol, and ipratropium on normal and impaired mucociliary function in sheep. Chest (2005) 0.85
Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr Med Chem Cardiovasc Hematol Agents (2003) 0.85
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis (2011) 0.85
Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy. Bioorg Med Chem (2007) 0.85